As the largest resource of information specific to women's brain health, we are sure you will find what you are looking for, and promise that you will discover new information.
Published on: December 18, 2012
by Tess Stynes for 4-Traders:
Merck & Co. reached a collaboration, license and supply agreement with General Electric Co.’s health-care business for use of a GE Healthcare investigational imaging agent to support the pharmaceutical company’s lead drug candidate to treat Alzheimer’s disease.
Merck’s investigational Alzheimer’s treatment–called MK-8931–targets a substance in the brain called amyloid. Scientists have hypothesized that the buildup of amyloid in the brain plays a role in Alzheimer’s disease. A number of major pharmaceutical companies have been looking for a treatment to stop the progression of the disease, which impairs memory and cognitive skills in the elderly.
Under the agreement GE Healthcare will supply Flutemetamol to help select patients for clinical trials and to evaluate the imaging agent used in positron emission tomography–or PET–scans as a companion diagnostic tool.
Further terms of the collaboration weren’t disclosed.
“There is a serious unmet need for a reliable method for measuring beta amyloid deposits to help physicians diagnose Alzheimer’s disease at its different stages and study its progression,” said Darryle Schoepp, head of neuroscience and ophthalmology at Merck Research Laboratories. “This agreement will allow us to employ an investigational imaging agent to help identify patients who might benefit from an anti-amyloid therapy and enable clinical evaluation” of MK-8931.”
Dementia is a progressively debilitating neurodegenerative condition. Early intervention and reducing its development by identifying its risk factors are the main goals in dementia treatment. This is particularly important as there is little...
Yale researchers have tested a new method for directly measuring synaptic loss in individuals with Alzheimer’s disease. The method, which uses PET imaging technology to scan for a specific protein in the brain linked to synapses, has...
Sometimes, the hardest part of living with a mental illness isn’t the symptoms, or the management — it’s dealing with stigma from other people. And unfortunately, many people who live with mental illness face stigma...
The material presented through the Think Tank feature on this website is in no way intended to replace professional medical care or attention by a qualified practitioner. WBHI strongly advises all questioners and viewers using this feature with health problems to consult a qualified physician, especially before starting any treatment. The materials provided on this website cannot and should not be used as a basis for diagnosis or choice of treatment. The materials are not exhaustive and cannot always respect all the most recent research in all areas of medicine.